Institute for Safe Medication Practices Lifetime Achievement Award 2011.

Lawrence A. Trissel was awarded the 2011 Institute for Safe Medication Practices Lifetime Achievement Award. In this article, the author acknowledges his appreciation of being selected for this award, pays his respects to those who honored him, and discusses the future of pharmacy as it relates to drug stability and compatibility efforts.

Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.

Purpose: The physical compatibility of ceftaroline fosamil with commonly used medications and diluents (a total of 73 drugs in 219 admixtures) during simulated Y-site administration was evaluated.

Methods: Duplicate 5-mL samples of ceftaroline fosamil (2.22 mg/mL) in 5% dextrose injection, 0.

Drug Compatibility with a New Generation of VISIV Polyolefin Infusion Solution Containers.

A new generation of VISIV polyolefin intravenous solution containers, made of a new and different proprietary polymer, were evaluated for sorption and leaching potential with a cadre of drugs known to exhibit those phenomena with polyvinylchloride containers. Sorption potential was evaluated for amiodarone hydrochloride, carmustine, regular human insulin, lorazepam, nitroglycerin, sufentanil citrate, and thiopental sodium. Leaching potential was evaluated for tacrolimus and teniposide as well as the vehicles of docetaxel and paclitaxel.

Compatibility and stability of palonosetron hydrochloride and propofol during simulated y-site administration.

Palonosetron hydrochloride is a longer-acting, selective 5-HT3 receptor antagonist that has been approved for prevention of chemotherapy-induced nausea and vomiting and is being evaluated for prevention of postoperative nause and vomiting. The objective of this study was to evaluate the physical and chemical stablity of palonosetron hydrochloride 50 mcg/mL when mixed with undiluted propofol 1% during simulated Y-site administation. Duplicate samples of this mixture were tested.

Quality-control analytical methods: overview of beyond-use dating for compounded sterile preparations.

United States Pharmacopeia Chapter 797 provides guidelines and standards that deal with the preparation, compounding, and labeling of compounded sterile preparations. These standards ensure patient care and safety by defining safe practice. The Chapter gives instructions on determining beyond-use dates for the different risk categories associated with compounded preparations.